Nuvilex (NASDAQ:PMCB) CEO Joshua Silverman Purchases 30,000 Shares

Nuvilex Inc. (NASDAQ:PMCB) CEO Joshua Silverman purchased 30,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were purchased at an average cost of $0.78 per share, for a total transaction of $23,400.00. Following the purchase, the chief executive officer directly owned 346,250 shares in the company, valued at approximately $270,075. This represents a 9.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Joshua Silverman also recently made the following trade(s):

• On Wednesday, January 7th, Joshua Silverman purchased 40,000 shares of Nuvilex stock. The stock was purchased at an average price of $0.83 per share, for a total transaction of $33,200.00.

Nuvilex Price Performance

NASDAQ PMCB opened at $0.83 on Thursday. The business has a 50 day moving average price of $0.84 and a 200 day moving average price of $0.95. The company has a market capitalization of $8.41 million, a P/E ratio of -0.60 and a beta of 0.04. Nuvilex Inc. has a 1-year low of $0.63 and a 1-year high of $1.90.

Nuvilex (NASDAQ:PMCB) last posted its earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nuvilex has an average rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.